Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · March 20, 2022

Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccine in Nonimmunocompromised Children and Adolescents

MMWR. Morbidity and Mortality Weekly Report


Additional Info

Disclosure statements are available on the authors' profiles:

MMWR. Morbidity and Mortality Weekly Report
Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022
MMWR Morb. Mortal. Wkly. Rep. 2022 Mar 04;71(9)352-358, NP Klein, MS Stockwell, M Demarco, M Gaglani, AB Kharbanda, SA Irving, S Rao, SJ Grannis, K Dascomb, K Murthy, EA Rowley, AF Dalton, MB DeSilva, BE Dixon, K Natarajan, E Stenehjem, AL Naleway, N Lewis, TC Ong, P Patel, D Konatham, PJ Embi, SE Reese, J Han, N Grisel, K Goddard, MA Barron, M Dickerson, IC Liao, WF Fadel, DH Yang, J Arndorfer, B Fireman, EP Griggs, NR Valvi, C Hallowell, O Zerbo, S Reynolds, J Ferdinands, MH Wondimu, J Williams, CH Bozio, R Link-Gelles, E Azziz-Baumgartner, SJ Schrag, MG Thompson, JR Verani

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading